Andreas Kerschbaumer
Overview
Explore the profile of Andreas Kerschbaumer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
2639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nash P, Kerschbaumer A, Konzett V, Aletaha D, Dorner T, Fleischmann R, et al.
Ann Rheum Dis
. 2025 Mar;
PMID: 40037995
In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy,...
2.
Konzett V, Smolen J, Nash P, Aletaha D, Winthrop K, Dorner T, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39934019
Objective: This systematic literature review (SLR) on efficacy outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with...
3.
Konzett V, Smolen J, Nash P, Winthrop K, Aletaha D, Dorner T, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39934016
Objectives: This systematic literature review (SLR) on safety outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with...
4.
Kecorius S, Sues S, Madueno L, Wiedensohler A, Winkler U, Held A, et al.
Environ Int
. 2024 Oct;
193:109086.
PMID: 39447469
Studies revealed airports as a prominent source of ultrafine particles (UFP), which can disperse downwind to residential areas, raising health concerns. To expand our understanding of how air traffic-related emissions...
5.
Kerschbaumer A, Smolen J, Ferreira R, Bertheussen H, Baraliakos X, Aletaha D, et al.
Ann Rheum Dis
. 2024 Mar;
83(6):760-774.
PMID: 38503473
Objectives: To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). Methods: This systematic literature research (SLR) investigated the efficacy and safety...
6.
Gossec L, Kerschbaumer A, Ferreira R, Aletaha D, Baraliakos X, Bertheussen H, et al.
Ann Rheum Dis
. 2024 Mar;
83(6):706-719.
PMID: 38499325
Objective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the...
7.
Winthrop K, Mease P, Kerschbaumer A, Voll R, Breedveld F, Smolen J, et al.
Ann Rheum Dis
. 2023 Dec;
83(4):409-416.
PMID: 38123338
The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the...
8.
Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz L, et al.
Ann Rheum Dis
. 2023 Nov;
83(2):139-160.
PMID: 37923366
Fundamental insight gained over the last decades led to the discovery of cytokines as pivotal drivers of inflammatory diseases such as rheumatoid arthritis, psoriasis/psoriasis arthritis, inflammatory bowel diseases, atopic dermatitis...
9.
Konzett V, Kerschbaumer A, Smolen J, Kristianslund E, Provan S, Kvien T, et al.
Ann Rheum Dis
. 2023 Oct;
83(2):169-176.
PMID: 37890977
Objective: To develop and validate definitions for disease flares in rheumatoid arthritis (RA) based on the quantitative Simplified and Clinical Disease Activity Indices (SDAI, CDAI). Methods: We analysed RA treatment...
10.
Konzett V, Kerschbaumer A, Smolen J, Aletaha D
Ann Rheum Dis
. 2023 Sep;
83(1):58-64.
PMID: 37758287
Objectives: To evaluate which American College of Rheumatology (ACR) response definition (ACR20, 50 or 70) should primarily be used for efficacy claims in future drug approval trials of rheumatoid arthritis...